etcembly.com | Etcembly | TCRs by intelligent

Robots.txt Information

Robot	Path	Permission
GoogleBot	/	✔
BingBot	/	✔
BaiduSpider	/	✔
YandexBot	/	✔
User-agent: * Allow: / # Optimization for Google Ads Bot User-agent: AdsBot-Google-Mobile User-agent: AdsBot-Google Disallow: /_api/* Disallow: /_partials* Disallow: /pro-gallery-webapp/v1/galleries/* # Block PetalBot User-agent: PetalBot Disallow: / Sitemap: https://www.etcembly.com/sitemap.xml # Auto generated, go to SEO Tools > Robots.txt Editor to change

Meta Tags

Title	Etcembly \| TCRs by intelligent
Description	ETCEMBLY - DEMYSTIFY T CELL RECEPTORS & UNLOCK A NEW WORLD OF IMMUNE THERAPIES --- Etcembly is building the world’s largest machine learning database and unmatched immunology expertise to deliver the safest and most powerful TCR immunotherapies
Keywords	N/A

Server Information

WebSite	etcembly.com
Host IP	23.236.62.147
Location	United States

Related Websites

                        Site
                        Rank
                    

More to Explore

etcembly.com Valuation

US$1,592

Last updated: 2023-05-20 07:57:36

etcembly.com has Semrush global rank of 0. etcembly.com has an estimated worth of US$ 1,592, based on its estimated Ads revenue. etcembly.com receives approximately 183 unique visitors each day. Its web server is located in United States, with IP address 23.236.62.147. According to SiteAdvisor, etcembly.com is safe to visit.

Traffic & Worth Estimates

Purchase/Sale Value	US$1,592
Daily Ads Revenue	US$1
Monthly Ads Revenue	US$44
Yearly Ads Revenue	US$529
Daily Unique Visitors	12
Note: All traffic and earnings values are estimates.

DNS Records

Host	Type	TTL	Data
etcembly.com.	A	86400	IP: 23.236.62.147
etcembly.com.	NS	86400	NS Record: ns2.phase8.net.
etcembly.com.	NS	86400	NS Record: ns0.phase8.net.
etcembly.com.	NS	86400	NS Record: ns1.phase8.net.
etcembly.com.	MX	86400	MX Record: 30 mailserver.cmp.livemail.co.uk.
etcembly.com.	TXT	86400	TXT Record: MailKey=y6XPxqf8hXDrbFy

HtmlToTextCheckTime:2023-05-20 07:57:36

top of page menu about the challenge introducing EMLy three pillars to success TCR optimisation our technology the benefits our team the partners contact careers news DEMYSTIFY T CELL RECEPTORS & UNLOCK A NEW WORLD OF IMMUNE THERAPIES Accelerate the pathway to clinical trials with our revolutionary machine learning platform Gain the upper hand in the evolutionary arms race between humans and pathogens intro film about ABOUT T Cell Receptors (TCRs) constitute one of the most promising classes of emerging therapeutics. Whilst TCRs are amongst the most complex facets of immune biology, engineering of an optimum T Cell Receptor can transform immunotherapies and personalised medicines. Etcembly is building the world’s largest machine learning database and unmatched immunology expertise to deliver the safest and most powerful TCR immunotherapies through rapid computer-assisted engineering. Intro film SUCCESSFUL IMMUNOTHERAPY RELIES ON UNDERSTANDING TWO HEMISPHERES PEPTIDE HEMISPHERE TCR

HTTP Headers

HTTP/1.1 301 Moved Permanently
Date: Wed, 25 Jan 2023 09:01:17 GMT
Content-Length: 0
Connection: keep-alive
location: https://www.etcembly.com/
strict-transport-security: max-age=3600
Age: 912
Server-Timing: cache;desc=hit, varnish;desc=hit, dc;desc=uw2-pub-1
X-Seen-By: tHzHG6QeSsyukPkElY9D5KnPWIDxfKj16yM6xXYJ3IE=,GXNXSWFXisshliUcwO20Naon851uhK6HRsxREnrEO9a3J7KfdiQDDBc3NNc5yr0pmuOkfcTSJaUOHlD2KQbqrA==,m0j2EEknGIVUW/liY8BLLrxJXV2YgYThePtFG+29vnIG/hKs8AeY1T4OIbgnD+yx,2d58ifebGbosy5xc+FRalmvr40SE5q0eaWefn+uaajewTy5qmU/5y4UV3hSjXyqBCdpirhh6DlhU7WK3dqX02Q==,2UNV7KOq4oGjA5+PKsX47O6uVG6buAunlWjI2L90d5VjPZTuGyYqVhtmEIgJUb4w
Cache-Control: no-cache
X-Wix-Request-Id: 1674637277.739208128935118217
X-Content-Type-Options: nosniff

HTTP/2 200 
date: Wed, 25 Jan 2023 09:01:18 GMT
content-type: text/html; charset=UTF-8
link: ; rel=preconnect; crossorigin;,; rel=preconnect;,; rel=preconnect; crossorigin;,; rel=preconnect;,; rel=preconnect; crossorigin;,
x-wix-request-id: 1674637277.95266679965022208
content-language: en
strict-transport-security: max-age=3600
age: 0
x-seen-by: GXNXSWFXisshliUcwO20NXdyD4zpCpFzpCPkLds0yMc33wO/HQrXTpULZAkVmKoc,qquldgcFrj2n046g4RNSVLeuNqwcdH46iMA2Je1RdMI=,2d58ifebGbosy5xc+FRalh27WUAXwQXOFOeFJpt2BmgycEh3SKJq6X5vTs1WypFXjoe2GMQJ/MdiMK4Y/vI70wIIkTOZGLBJPIvcX184Sn8=,2UNV7KOq4oGjA5+PKsX47NUasjswhNGIXbIBRNNYqttWd3xniMsr1HjrszKGvMzr,7npGRUZHWOtWoP0Si3wDp3pk+fOCkUHYAkRreQULO2E=,m86p0LbwQP79i4nFFg3Ypk1kFV3G2pd/2Iby4grHOqWgTyWDFLZXCkdAZ7i/t+i6b43VuqHMXN8VQ1HEdkfKow==,xTu8fpDe3EKPsMR1jrheELbJcRgsKUIwnMTcz8ixkcw=,xTu8fpDe3EKPsMR1jrheEP5gtScAJJrw2JFX4+Usu98=,LoUK8/saGAmOxZWtpubo2nplp21VfQd7g5CMhlekCpgr3H4w4NMgH6xcspqaEaXl61gNMH6k0dOeFVTaJ0zP4w==,xTu8fpDe3EKPsMR1jrheEP5gtScAJJrw2JFX4+Usu98=,xTu8fpDe3EKPsMR1jrheEPBi2w4NwvKRM89yrhnb94k=,/a5ccLSK1HEmwPNg/x6OukIT+c5HqyHveWvXmN7dchq1KpiGu/ZcJyKY8+4N14N9fPMcdw2s2NMij1P/Ud3EaVwkJA2w5TwsU3NEoJbH6x4=
cache-control: no-cache
vary: Accept-Encoding
accept-ranges: bytes
set-cookie: ssr-caching=cache#desc=miss#varnish=miss#dc#desc=euw3_g; Max-Age=20; Expires=Wed, 25 Jan 2023 09:01:38 GMT
server-timing: cache;desc=miss, varnish;desc=miss, dc;desc=euw3_g
x-content-type-options: nosniff
server: Pepyaka/1.19.10
via: 1.1 google
alt-svc: h3=":443"; ma=2592000,h3-29=":443"; ma=2592000,h3-Q050=":443"; ma=2592000,h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000,quic=":443"; ma=2592000; v="46,43"

etcembly.com valuation and analysis